Program
romiplostim
Also written as “Romiplostim”, “AMG 531” and “GNR-069”.
Its studies are mostly in Purpura, Thrombocytopenic, Idiopathic · Anemia, Aplastic · Myelodysplastic Syndromes · Carcinoma, Non-Small-Cell Lung · Purpura, Thrombocytopenic, led by 5 companies.
Drug pageRomiplostim: every studyMany companies study it; this page follows only the 38 they lead. All 90 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Amgenits history only | 252 open or running | phase 4since May 21, 2009 | Jan 27, 2005 | Sep 14, 2029phase 3 · NCT07700238 |
| Kyowa Kirinits history only | 80 open or running | phase 3since Feb 22, 2007 | Mar 20, 2006 | none ahead |
| AO GENERIUMits history only | 20 open or running | phase 3since Jan 21, 2022 | Jan 21, 2022 | none ahead |
| Geropharmits history only | 21 open or running | phase 3since Jul 4, 2024 | Dec 7, 2022 | Mar 31, 2028phase 3 · NCT06497036 |
| Qilu Pharmaceuticalits history only | 11 open or running | phase 3since Dec 23, 2025 | Dec 23, 2025 | Oct 2029phase 3 · NCT07345000 |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of every company. Pick one to see its own:
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 23 studies since Jan 27, 2005.
- May 9, 2016Phase 3 study in Anemia, AplasticKyowa Kirin · NCT02773290 · 46 enrolled · Japan, Korea, Republic of
- Aug 11, 2016Phase 3 study in Purpura, Thrombocytopenic, IdiopathicKyowa Kirin · NCT02868099 · 203 enrolled · China
- Aug 11, 2016Phase 2 study in Purpura, Thrombocytopenic, IdiopathicKyowa Kirin · NCT02868060 · 16 enrolled · China
- Oct 12, 20172 phase 3 studiesAmgen · NCT03362177, NCT03343847
- Apr 24, 2019Phase 3 study in Carcinoma, Non-Small-Cell LungAmgen · NCT03937154 · 145 enrolled · United States, Argentina, Brazil and more
- May 9, 2019Phase 3 study in Anemia, AplasticKyowa Kirin · NCT03957694 · 17 enrolled · Japan
- Sep 18, 2019Phase 3 study in Anemia, AplasticKyowa Kirin · NCT04095936 · 24 enrolled · Japan
- Jan 21, 2022AO GENERIUM’s first study: phase 3 study in Purpura, Thrombocytopenic, IdiopathicNew to AO GENERIUMAO GENERIUM · NCT05220878 · 160 enrolled · Russian Federation
- Apr 5, 2022Phase 2 study in Anemia, AplasticAmgen · NCT05323617
- Aug 3, 2022Phase 3 study in Purpura, Thrombocytopenic, IdiopathicAO GENERIUM · NCT05492409 · 160 enrolled · Russian Federation
- Dec 7, 2022Geropharm’s first study: phase 1 study in PharmacodynamicsNew to GeropharmGeropharm · NCT05652595 · 56 enrolled · Russian Federation
- Jul 4, 2024Phase 3 study in Drug EffectGeropharm · NCT06497036 · 160 enrolled · Russian Federation
- Dec 23, 2025Qilu Pharmaceutical’s first study: phase 3 study in Treatment-naïve Severe Aplastic AnemiaNew to Qilu PharmaceuticalQilu Pharmaceutical · NCT07345000 · 210 planned
- Jul 7, 2026Phase 3 study in Purpura, Thrombocytopenic, IdiopathicAmgen · NCT07700238 · 126 planned · United States, Germany, Hungary and more
Ahead
- Mar 31, 2028Primary completion: phase 3 study in Drug EffectGeropharm · NCT06497036
- Sep 14, 2029Primary completion: phase 3 study in Purpura, Thrombocytopenic, IdiopathicAmgen · NCT07700238
- Oct 2029Primary completion: phase 3 study in Treatment-naïve Severe Aplastic AnemiaQilu Pharmaceutical · NCT07345000
TargetBeta
“Thrombopoietin receptor agonist”ChEMBL 37, by rule
Other programs on MPL
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| eltrombopagrule | GlaxoSmithKline | phase 4 | 49 |
| avatrombopagrule | Eisai | phase 4 | 25 |
| hetrombopag olaminerule | Jiangsu HengRui Medicine | phase 3 | 15 |
Studies
All 38 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07700238Purpura, Thrombocytopenic, Idiopathic · United States, Germany, Hungary and more | 3 | Recruiting | Amgen | Sep 14, 2029 | 126 |
| NCT07345000Treatment-naïve Severe Aplastic Anemia | 3 | Not yet recruiting | Qilu Pharmaceutical | Oct 2029 | 210 |
| NCT06497036Drug Effect · Russian Federation | 3 | Active, not recruiting | Geropharm | Mar 31, 2028 | 160 |
| NCT05652595Pharmacodynamics · Russian Federation | 1 | UNKNOWN | Geropharm | Jun 30, 2024 | 56 |
| NCT05492409Purpura, Thrombocytopenic, Idiopathic · Russian Federation | 3 | Completed | AO GENERIUM | Apr 3, 2024 | 160 |
| NCT05323617Anemia, Aplastic | 2 | Withdrawn | Amgen | Feb 25, 2025 | 0 |
| NCT05220878Purpura, Thrombocytopenic, Idiopathic · Russian Federation | 3 | Completed | AO GENERIUM | Aug 22, 2023 | 160 |
| NCT04095936Anemia, Aplastic · Japan | 3 | Completed | Kyowa Kirin | Oct 7, 2021 | 24 |
| NCT03957694Anemia, Aplastic · Japan | 3 | Completed | Kyowa Kirin | Nov 5, 2020 | 17 |
| NCT03937154Carcinoma, Non-Small-Cell Lung · United States, Argentina, Brazil and more | 3 | Active, not recruiting | Amgen | Mar 10, 2026 | 145 |
| NCT03362177Gastrointestinal Neoplasms · United States, Argentina, Austria and more | 3 | Completed | Amgen | Jan 25, 2024 | 165 |
| NCT03343847Chemotherapy-induced Thrombocytopenia | 3 | Withdrawn | Amgen | Jul 17, 2021 | 0 |
| NCT02868099Purpura, Thrombocytopenic, Idiopathic · China | 3 | Completed | Kyowa Kirin | Feb 2017 | 203 |
| NCT02868060Purpura, Thrombocytopenic, Idiopathic · China | 2 | Completed | Kyowa Kirin | Aug 2017 | 16 |
| NCT02773290Anemia, Aplastic · Japan, Korea, Republic of | 3 | Completed | Kyowa Kirin | Nov 14, 2017 | 46 |
| NCT02279173Purpura, Thrombocytopenic, Idiopathic · United States, Australia, Belgium and more | 3 | Completed | Amgen | Aug 30, 2018 | 203 |
| NCT02094417Anemia, Aplastic · Korea, Republic of | 2 | Completed | Kyowa Kirin | Apr 24, 2017 | 35 |
| NCT01444417Purpura, Thrombocytopenic, Idiopathic · United States, Australia, Canada | 3 | Completed | Amgen | Feb 2015 | 62 |
| NCT01143038Purpura, Thrombocytopenic, Idiopathic · United States, Australia, Czechia and more | 2 | Completed | Amgen | Sep 20, 2013 | 75 |
| NCT01071954Purpura, Thrombocytopenic, Idiopathic · United States, Australia, Canada and more | 3 | Completed | Amgen | Jan 12, 2017 | 66 |
| NCT00907478Thrombocytopenia | 4 | Completed | Amgen | Jan 9, 2014 | 169 |
| NCT00614523Myelodysplastic Syndromes | 2 | Completed | Amgen | Mar 31, 2011 | 250 |
| NCT00515203Purpura, Thrombocytopenic, Idiopathic | 2 | Completed | Amgen | Mar 2009 | 22 |
| NCT00508820Purpura, Thrombocytopenic, Idiopathic | 3 | Completed | Amgen | Jan 1, 2011 | 407 |
| NCT00472290Myelodysplastic Syndromes | – | Completed | Amgen | Jul 18, 2011 | 72 |
| NCT00440037Purpura, Thrombocytopenic · Japan | 3 | Completed | Kyowa Kirin | Jul 2011 | 44 |
| NCT00418665Myelodysplastic Syndromes | 2 | Completed | Amgen | Mar 2009 | 39 |
| NCT00415532Purpura, Thrombocytopenic, Idiopathic | 3 | Completed | Amgen | Nov 7, 2008 | 234 |
| NCT00413283Lung Neoplasms · United States, Austria, Canada and more | 2 | Completed | Amgen | Dec 2008 | 63 |
| NCT00321711Myelodysplastic Syndromes | 2 | Completed | Amgen | Oct 19, 2009 | 69 |
| NCT00305435Purpura, Thrombocytopenic | 2 | Completed | Kyowa Kirin | Nov 2006 | 12 |
| NCT00303472Thrombocytopenia | 2 | Completed | Amgen | May 2008 | 72 |
| NCT00283439Hodgkin Disease | 2 | Completed | Amgen | May 2008 | 39 |
| NCT00117143Purpura, Thrombocytopenic | 2 | Completed | Amgen | Jul 19, 2004 | 16 |
| NCT00116688Thrombocytopenia | 3 | Completed | Amgen | Jan 2010 | 313 |
| NCT00111475Purpura, Thrombocytopenic, Idiopathic | 2 | Completed | Amgen | Jun 17, 2004 | 45 |
| NCT00102336Thrombocytopenia | 3 | Completed | Amgen | Dec 1, 2006 | 62 |
| NCT00102323Thrombocytopenia | 3 | Completed | Amgen | Sep 1, 2006 | 63 |
How it is read
Names in the registry
- “Romiplostim”, 22 entries
- “AMG 531”, 6 entries
- “GNR-069”, 2 entries
- “Romiplostim N01”, 1 entry
- “GP404141”, 1 entry
Conditions, from the studies’ own filings
- Purpura, Thrombocytopenic, Idiopathic, 18 studies
- Anemia, Aplastic, 6 studies
- Myelodysplastic Syndromes, 4 studies
- Carcinoma, Non-Small-Cell Lung, 2 studies
- Purpura, Thrombocytopenic, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.